NATALIA DE LAS
HERAS JIMÉNEZ
Profesora titular de universidad
![Foto de NATALIA DE LAS](/img/nophoto.png)
![Foto de Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer](/img/noimage_org.png)
Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer
Salamanca, EspañaPublicacións en colaboración con investigadores/as de Instituto de Biología Molecular y Celular del Cáncer de Salamanca / Centro de Investigación del Cáncer (8)
2016
-
Minimal residual disease evaluation by flow cytometry is a complementary tool to cytogenetics for treatment decisions in acute myeloid leukaemia
Leukemia Research, Vol. 40, pp. 1-9
2013
-
Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine
Annals of Hematology, Vol. 92, Núm. 11, pp. 1543-1552
2011
-
Competition between clonal plasma cells and normal cells for potentially overlapping bone marrow niches is associated with a progressively altered cellular distribution in MGUS vs myeloma
Leukemia, Vol. 25, Núm. 4, pp. 697-706
-
The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis
Blood, Vol. 117, Núm. 13, pp. 3613-3616
2009
-
Soluble and membrane levels of molecules involved in the interaction between clonal plasma cells and the immunological microenvironment in multiple myeloma and their association with the characteristics of the disease
International Journal of Cancer, Vol. 124, Núm. 2, pp. 367-375
-
The persistence of immunophenotypically normal residual bone marrow plasma cells at diagnosis identifies a good prognostic subgroup of symptomatic multiple myeloma patients
Blood, Vol. 114, Núm. 20, pp. 4369-4372
2008
-
Multiparameter flow cytometric remission is the most relevant prognostic factor for multiple myeloma patients who undergo autologous stem cell transplantation
Blood, Vol. 112, Núm. 10, pp. 4017-4023
2004
-
Proliferative activity of plasma cells is the most relevant prognostic factor in elderly multiple myeloma patients
International Journal of Cancer, Vol. 112, Núm. 5, pp. 884-889